CPI-613 or known as Polichrome-1 is a novel anti-cancer compound that is currently being studied for its potential in cancer treatment. It is a novel lipoate analog that targets cancer cell metabolism, making it a promising anti-cancer agent. CPI-613’s chemical name is 6,8-bis(benzylthio)octanoic acid, and it has a molecular formula of C18H26O4S2 with a formula weight of 386.53 g/mol. Its CAS No is 95809-78-2. CPI-613 is considered an orphan drug by the FDA and is classified as an Investigational New Drug (IND).
Top Ten Keywords: CPI-613, orphan drug, cancer treatment, metabolism, anti-cancer agent, FDA, Investigational New Drug, clinical trial, cancer cell, lipoate analog.
Synonyms: Polichrome-1, Devimistat, CPI-613.
Health Benefits of CPI-613: CPI-613 is a potential cancer treatment that targets cancer cell metabolism, which differs from non-cancerous cells. It works by blocking two key enzymes that are essential to the metabolism of cancer cells, pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. By disrupting these enzymes, CPI-613 can cause cancer cells to die or become more susceptible to other treatments. CPI-613 has been tested in clinical trials for various types of cancer, including pancreatic, lung, and leukemia.
Potential Effects: CPI-613 has been shown to have various potential effects on cancer cells. Studies show that CPI-613 can induce apoptosis, or programmed cell death, in cancer cells. Additionally, it can disrupt cancer cell metabolism, leading to decreased cell proliferation and increased vulnerability to other treatments such as radiation and chemotherapy. CPI-613 has also been shown to have minimal effects on non-cancerous cells, making it less toxic than traditional cancer treatments.
Product Mechanism: CPI-613 operates by inhibiting two key enzymes in the tricarboxylic acid (TCA) cycle of cancer cells, pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. By inhibiting these enzymes, CPI-613 disrupts the metabolism of cancer cells and decreases their growth rate. The inhibition of these enzymes also leads to the accumulation of reactive oxygen species (ROS) in cancer cells, which triggers apoptosis.
Safety: CPI-613 has been tested in clinical trials and has been found to be relatively safe. Adverse effects were primarily mild or moderate in most instances, such as nausea, vomiting, and diarrhea. CPI-613 has also demonstrated low toxicity to non-cancerous cells.
Side Effects: CPI-613’s side effects have been relatively mild, with adverse events occurring at a similar rate to those of placebo. Some of the most common side effects of CPI-613 include nausea, vomiting, and diarrhea. CPI-613 can also cause mild bone marrow suppression, which could lead to mild anemia, but severe hematologic toxicity was not observed.
Dosing Information: CPI-613 dosages can vary depending on the type of cancer and the patient. A recommended dose of CPI-613 is 500-3000 mg/m2 when used alone and 500-2000 mg/m2 in combination with other chemotherapy treatments. Treatment cycles range from 1-21 days, and the dose is usually infused over two hours.
In conclusion, CPI-613 is a promising cancer treatment that targets cancer cell metabolism, making it less toxic than traditional chemotherapy treatments. Its inhibition of key enzymes in the TCA cycle makes it a novel anti-cancer agent that has been tested in clinical trials for various types of cancer. CPI-613 is relatively safe, with minor adverse effects, making it a potential breakthrough in the field of cancer treatment. Still, further studies are necessary to determine its efficacy and safety consistently.
